
    
      30 subjects treated with etanercept or adalimumab for at least 24 weeks with a body surface
      area 2-10% and physician global assessment greater than or equal to 2 will receive EnstilarÂ®
      once daily for 4 weeks followed by QOD for 12 weeks.
    
  